secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cardiff Oncology, Inc. (CRDF)
CIK:        0001213037
Form:       8-K
Filed at:   2022-11-03T23:59:59+00:00
Accession:  0001628280-22-028200
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cardiff Oncology Q3 cash burn $7.5M; Phase 1b/2 mCRC data show 35% ORR; ONSEMBLE trial on track for Q4 activation
--------------------------------------------------------------------------------

- Cash, equivalents, and investments $114M as of Sep 30, 2022; projected runway into 2025.
- Q3 2022 net cash used in operations $7.5M vs $5.5M in Q3 2021.
- Phase 1b/2 mCRC trial: ORR 35% (n=48), mPFS 9.3 months, mDoR 11.7 months.
- ONSEMBLE randomized Phase 2 trial in KRAS/NRAS-mutated mCRC activation expected Q4 2022.
- Bevacizumab-naïve subgroup ORR 69% and mPFS 13.5 months vs historical ~25% and 6.9 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1213037/000162828022028200/0001628280-22-028200-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1213037/000162828022028200/crdf-20221103.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-028200

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer